Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma

NCT01555892 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT01555892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01555892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of Rapidly Generated EBV-Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
January 14, 2013
Completion date
July 1, 2027
Enrollment
136 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's disease, lymphoma, lymphoproliferative disease, non-hodgkin's lymphoma